That reminds me of that one time a shareholder told a fairy tale about fabricated checkmate data and attempted to put NWBO in a bad light based on this fairy tale data.
Duffy went back to Merck after helping UCLA with combination trial design and helped NWBO with the SAP, imo. The SAP help would have been essential, because Merck makes Temodar and they would have more access to ECA data than any other company in the world. Imo.
Yet another reason a BP looks like they are pulling the strings.